Takaisin Tulosta

The number needed to treat (NNT) and cost per responder for weight loss drugs for overweight and obesity

Additional information
Kaisu Happonen, Eila Kankaanpää, Juha Ahonen and Salla Mattila
17.11.2026

This appendix describes in detail the effectiveness evidence and cost information on weight loss drugs for overweight and obesity. The effectiveness evidence for this analysis was derived from Current Care guideline evidence summaries, selected in collaboration with the Obesity Current Care Guideline group. These evidence summaries formed the primary basis for identifying relevant randomized controlled trials. The findings from the evidence summaries were compared with the results of the network meta-analysis conducted by McGowan et al. (2025) «McGowan B, Ciudin A, Baker JL, et al. A systematic...»13 to assess consistency of the effect estimates. The randomized controlled trials included from the evidence summaries are presented in Table «Table 2. Included studies of chosen interventions ...»2.

Source of the effectiveness evidence

«In adults with BMI≥30 kg/m2 or BMI≥27 kg/m2 and at least one weight-related comorbidity, once-weekly subcutaneous semaglutide 2.4 mg results in substantial weight loss compared to placebo, with a mean difference of approximately 11-12%, over follow-up periods ranging from 1-3 years.»A, «In adults with BMI≥30 kg/m2 or BMI≥27 kg/m2 and at least one weight-related comorbidity, once-weekly subcutaneous tirzepatide 5-15 mg results in substantial weight loss compared to placebo, with a mean difference of approximately 11-20%, over follow-up periods ranging from 1-3 years. Individuals with type II diabetes typically present somewhat lower weight loss percentages; mean difference compared to placebo: 10-12%.»A, «In adults with overweight (BMI ≥27 kg/m²) and obesity-related comorbidities or severe obesity (BMI >35 kg/m2), daily oral phentermine-topiramate 7.5/46 mg or 15/92 mg results in clinically meaningful, dose-dependent weight loss compared to placebo, with an average reduction in total body weight of approximately 7- 9% over follow-up periods ranging from 1 to 2 years.»B, «In adults with obesity or overweight (BMI ≥30 or ≥27 with comorbidities), liraglutide 3.0 mg once daily, combined with lifestyle counseling, likely leads to a weight loss of approximately 3–5% compared to placebo over a follow-up period of 1–3 years.»B, «In adults with obesity or overweight (BMI ≥ 27 kg/m²), naltrexone 32 mg and bupropion 360 mg daily combined with lifestyle counseling may result in 4–5 % greater weight loss than placebo over 56 weeks. Individuals with type II diabetes present weight loss numbers of 3% compared to placebo.»C

Literature selection

The effectiveness evidence and cost information are based on the evidence summaries of the Current Care guidelines. From these summaries, randomized controlled trials (RCTs) in which outcomes aligned with 5% and 10% weight loss targets were selected.

The Current Care guidelines evidence summaries were compared with the results of the network meta-analysis by McGowan etal. (2025) «McGowan B, Ciudin A, Baker JL, et al. A systematic...»13, including the number needed to treat (NNT) estimates and cost per treatment response calculated based on the network meta-analysis. Network meta-analysis was not used as a basis for the effectiveness evidence and cost information because individuals with and without diabetes were not analyzed as separate groups. In the network meta-analysis «McGowan B, Ciudin A, Baker JL, et al. A systematic...»13, these populations were pooled. However, in the effectiveness and cost evaluations, non-diabetic and diabetic populations were examined separately to improve clarity and comparability of the results.

The NNT estimates derived from the Current Care Guideline evidence summaries were compared with those based on McGowan etal. (2025) network meta-analysis «McGowan B, Ciudin A, Baker JL, et al. A systematic...»13. Overall, the results were closely aligned across both the 5% and 10% weight loss targets, with similar relative effectiveness observed between pharmacological treatments. For some treatments, the NNT values reported by McGowan et al. (2025) were slightly lower than those calculated in this analysis. This difference is largely explained by methodological choices. McGowan etal. (2025) did not stratify results by diabetes status, whereas the present analysis reports separate estimates for non-diabetic and diabetic populations. Consistent with this, NNTs were generally lower among non-diabetic individuals and higher among those with diabetes, with the McGowan et al. (2025) estimates typically falling between these subgroup-specific values. Confidence intervals for the calculated NNTs could not be estimated because these were not consistently reported for responders in the individual studies included in the Current Care guidelines evidence summaries.

The effectiveness evidence

We calculated the absolute risks (AR) of studies included in Current Care Guideline evidence summaries, and based on ARs, the absolute risk reduction (ARR) between the intervention and control groups. The number needed to treat (NNT) was derived from the ARR using the following formula:

NNT = 1/ ARR

Current Care Guideline evidence summaries included 28 RCTs of selected interventions which were compared against placebo. We used the results that were reported for participants achieving 5% and 10% weight loss. We have calculated the assumed comparator risk (ACR) as the weighted average of the RCTs placebo groups' weight-loss results.  The characteristics of RCTs are presented in table 2. The inclusion criteria varied between studies. Also, the study duration varied and was between 52 weeks and three years.

Costs of medicines

The costs of the medicines are from drug database available at Terveysportti health portal (Duodecim Publishing Company Ltd). We use retail prices based on the cheapest product price per dose of the medical substance in question. All package sizes are included in the comparison to find the cheapest dose.

The calculations are presented for two different time periods, one to present the cost for maintenance dose (52-week period) and another to present the cost for reaching the effectiveness target (56-week period which was a common length of follow-up period in the RCT studies). We calculated the cost per period based on cost per dose, and the number of doses needed. The dosing schedule does not always match with the 52 week or the 56-week period. In these cases, we use the costs that cover only the length of the period (i.e. we use decimals of doses). The cost-effectiveness calculation has been based on the dosing schedule shown below (Table «Dosing schedule ...»1).

Table 1. Dosing schedule

 

Table 2. Table 2. Included studies of chosen interventions
Study Intervention and comparison Study duration (weeks) Study population
Moiz 2024
includes STEP 1, 3, 5 and 8 «Moiz A, Levett JY, Filion KB, et al. Long-Term Eff...»14
Intervention: Once-weekly subcutaneous semaglutide 2.4 mg + lifestyle intervention (diet and physical activity). Comparison: Placebo injection + identical lifestyle intervention. 68─111 3,087 adults ≥18 years of age with BMI≥30 kg/m2 or BMI≥27 kg/m2 and at least one weight-related comorbidity, without diabetes, recruited from multiple countries.
Davies 2021
STEP 2 «Davies M, Færch L, Jeppesen OK, et al. Semaglutide...»4
  1. semaglutide 2.4 mg
  2. semaglutide 1.0 mg
  3. visually matching placebo

All groups received a lifestyle intervention. Use of peroral drugs for diabetes was permitted.
68 1,210 adults with a BMI of at least 27 kg/m2 and HbA1c 7–10% (53–86 mmol/mol) and diagnosis of type II diabetes.
149 outpatient clinics in 12 countries.
McGowan 2024
STEP 10 «McGowan BM, Bruun JM, Capehorn M, et al. Efficacy ...»12
Semaglutide 2.4 mg subcutaneously once weekly compared to placebo, both with lifestyle intervention.
Dose escalation to 2.4 mg over 16 weeks, treatment lasted 52 weeks followed by 28-week off-treatment period.
52 207 participants aged 18 years or older with a BMI of ≥30 kg/m² and prediabetes (HbA1c 6–6.4%, 42-47 mmol/mol or fasting plasma glucose 5.5-6.9 mmol/L).
30 trial sites in Canada, Denmark, Finland, Spain, and the UK.
Jastreboff et al., 2022
SURMOUNT-1 «Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepa...»9
Tirzepatide 5 mg, 10 mg, or 15 mg weekly vs. placebo. 72-week treatment including 20-week dose escalation period; all groups received standardized lifestyle counseling 72 2539 adults with BMI ≥30 or ≥27 + ≥1 weight-related complication, without diabetes. Conducted in nine countries at 119 sites.
Garvey et al., 2023 SURMOUNT-2 «Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepa...»6 Once-weekly tirzepatide 10 mg or 15 mg vs placebo for 72 weeks, with standardized lifestyle counselling. 72 938 adults with obesity or overweight and type 2 diabetes (BMI ≥27 kg/m², HbA1c 7–10%), 7 countries, 77 sites.
Jastreboff et al 2024
SURMOUNT-1 «Jastreboff AM, le Roux CW, Stefanski A, et al. Tir...»10
Tirzepatide 5, 10 or 15mg or placebo for 176 weeks, followed by a 17 week off-treatment period
All participants received lifestyle counseling.
176 1032 adult patients with BMI ≥30 or ≥27 with at least one obesity-related complication and prediabetes. Study sites in multiple countries.
Wadden et al. 2023
SURMOUNT-3 «Wadden TA, Chao AM, Machineni S, et al. Tirzepatid...»18
Patients who achieved ≥5.0% weight reduction after a 12-week intensive
lifestyle intervention were randomized to tirzepatide (maximum tolerated dose, 10 or 15 mg weekly) vs. placebo for 72 weeks.
72 579 adults with body mass index ≥30 or ≥27 kg/m2 and at least one obesity-related complication (excluding diabetes). Conducted in Argentina, Brazil, and USA.
Gadde et al. 2011
CONQUER «Gadde KM, Allison DB, Ryan DH, et al. Effects of l...»5
Three groups:
Placebo, phentermine+topiramate 7.5/46 mg, phentermine+topiramate 15/92 mg. Oral administration. All groups received lifestyle counseling
56 Adults aged 18-70 years with BMI 27-45 kg/m2 and two or more obesity-related comorbidities (hypertension, dyslipidemia, diabetes or prediabetes, abdominal obesity).
Garvey et al. 2011
SEQUEL «Garvey WT, Ryan DH, Look M, et al. Two-year sustai...»19
Three groups: Phentermine/topiramate 7.5/46 mg, 15/92 mg or placebo. Oral administration. All groups received lifestyle counseling. 108 Adults with BMI 27–45 kg/m² and ≥2 obesity-related comorbidities (hypertension, dyslipidemia, diabetes, abdominal obesity).
Allison et al. 2011
EQUIP «Allison DB, Gadde KM, Garvey WT, et al. Controlled...»1
Three groups: Phentermine/topiramate 3.75/23 mg, 15/92 mg or placebo. Oral administration. All groups received lifestyle counseling including a 500 kcal/day energy deficit. 56 Adults 18–70 years with severe obesity BMI ≥35 kg/m².
Pi-Sunyer et al. 2015
SCALE «Pi-Sunyer X, Astrup A, Fujioka K, et al. A Randomi...»15
Liraglutide 3.0 mg daily vs. placebo, both with lifestyle modification counseling for 56 weeks. 56 3731 adults (BMI ≥30 or ≥27 with comorbidities), 18+ yrs, without severe psychiatric disorders or diabetes; 61.2% had prediabetes. Multisite study.
Davies et al 2015
SCALE «Davies MJ, Bergenstal R, Bode B, et al. Efficacy o...»3
Three groups:
1) liraglutide 3 mg s.c. x
2) liraglutidi 1,8 mg s.c. x 1
3) placebo
All groups received 0-3 oral medications for diabetes (sulfonylurea/metformin/ thiazolidinedione) and lifestyle counselling
56 846 adult patients with type II diabetes and BMI >27 kg/m2, HbA1c 7-10%
Le Roux et al. 2017
SCALE «le Roux CW, Astrup A, Fujioka K, et al. 3 years of...»11
Liraglutide 3.0 mg subcutaneous daily vs. placebo, both combined with standardized monthly lifestyle counseling (dietary and physical activity advice). Intervention duration was 160 weeks with an additional 12-week off-treatment follow-up period. 160 2254 adults with prediabetes and BMI ≥30 kg/m², or ≥27 kg/m² with treated or untreated dyslipidemia or hypertension. Multisite study.
Wadden et al. 2020
SCALE IBT «Wadden TA, Tronieri JS, Sugimoto D, et al. Liraglu...»17
Liraglutide 3.0 mg/day vs. placebo, both combined with standardized intensive behavioral therapy (IBT, 23 brief counseling sessions over 56 weeks). 56 282 adults (≥18 yrs) with obesity (BMI ≥30 kg/m²), without diabetes. Multisite study.
Davies et al. 2017 «Davies MJ, Aronne LJ, Caterson ID, et al. Liraglut...»20 Liraglutide (up to 3.0 mg daily) compared to placebo or orlistat, alongside dietary and exercise advice given monthly. up to 3 years 5908 participants, BMI ≥27 kg/m² with ≥1 weight-related comorbidity or BMI ≥30 kg/m².
Greenway FL et al. 2010 COR-I «Greenway FL, Fujioka K, Plodkowski RA, et al. Effe...»7 Sustaine-released naltrexone 32 mg + bupropion 360 mg or naltrexone 16 mg + bupropion 360 mg per day vs. placebo for 56 weeks. 56 1742 adults aged 18–65 years, BMI 30–45 kg/m² or 27–45 kg/m² with dyslipidemia or hypertension.
Apovian CM et al. 2013
COR-II «Apovian CM, Aronne L, Rubino D, et al. A randomize...»2
Sustaine-released naltrexone 32 mg + bupropion 360 mg vs. placebo for 56 weeks. 56 1496 adults, BMI 30–45 kg/m² or 27–45 kg/m² with dyslipidemia or hypertension.
Wadden TA et al. 2011
COR-BMOD «Wadden TA, Foreyt JP, Foster GD, et al. Weight los...»16
Naltrexone SR 32 mg + Bupropion SR 360 mg + intensive behavioral modification vs. placebo + intensive behavioral modification for 56 weeks. 56 793 adults aged 18–65 years with obesity (BMI 30–45 kg/m²) and no major comorbidities.
Hollander P et al. 2013
COR-Diabetes «Hollander P, Gupta AK, Plodkowski R, et al. Effect...»8
Naltrexone SR 32 mg + Bupropion SR 360 mg vs. placebo for 56 weeks. 56 505 adults with type 2 diabetes, BMI ≥27 kg/m².

References

  1. Allison DB, Gadde KM, Garvey WT, et al. Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity (Silver Spring) 2012;20(2):330-42 «PMID: 22051941»PubMed
  2. Apovian CM, Aronne L, Rubino D, et al. A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). Obesity (Silver Spring) 2013;21(5):935-43 «PMID: 23408728»PubMed
  3. Davies MJ, Bergenstal R, Bode B, et al. Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial. JAMA 2015;314(7):687-99 «PMID: 26284720»PubMed
  4. Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet 2021;397(10278):971-984 «PMID: 33667417»PubMed
  5. Gadde KM, Allison DB, Ryan DH, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet 2011;377(9774):1341-52 «PMID: 21481449»PubMed
  6. Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 2023;402(10402):613-626 «PMID: 37385275»PubMed
  7. Greenway FL, Fujioka K, Plodkowski RA, et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2010;376(9741):595-605 «PMID: 20673995»PubMed
  8. Hollander P, Gupta AK, Plodkowski R, et al. Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. Diabetes Care 2013;36(12):4022-9 «PMID: 24144653»PubMed
  9. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med 2022;387(3):205-216 «PMID: 35658024»PubMed
  10. Jastreboff AM, le Roux CW, Stefanski A, et al. Tirzepatide for Obesity Treatment and Diabetes Prevention. N Engl J Med 2025;392(10):958-971 «PMID: 39536238»PubMed
  11. le Roux CW, Astrup A, Fujioka K, et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. Lancet 2017;389(10077):1399-1409 «PMID: 28237263»PubMed
  12. McGowan BM, Bruun JM, Capehorn M, et al. Efficacy and safety of once-weekly semaglutide 2·4 mg versus placebo in people with obesity and prediabetes (STEP 10): a randomised, double-blind, placebo-controlled, multicentre phase 3 trial. Lancet Diabetes Endocrinol 2024;12(9):631-642 «PMID: 39089293»PubMed
  13. McGowan B, Ciudin A, Baker JL, et al. A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults. Nat Med 2025;31(10):3317-3329 «PMID: 41039116»PubMed
  14. Moiz A, Levett JY, Filion KB, et al. Long-Term Efficacy and Safety of Once-Weekly Semaglutide for Weight Loss in Patients Without Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Am J Cardiol 2024;222():121-130 «PMID: 38679221»PubMed
  15. Pi-Sunyer X, Astrup A, Fujioka K, et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med 2015;373(1):11-22 «PMID: 26132939»PubMed
  16. Wadden TA, Foreyt JP, Foster GD, et al. Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obesity (Silver Spring) 2011;19(1):110-20 «PMID: 20559296»PubMed
  17. Wadden TA, Tronieri JS, Sugimoto D, et al. Liraglutide 3.0 mg and Intensive Behavioral Therapy (IBT) for Obesity in Primary Care: The SCALE IBT Randomized Controlled Trial. Obesity (Silver Spring) 2020;28(3):529-536 «PMID: 32090517»PubMed
  18. Wadden TA, Chao AM, Machineni S, et al. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial. Nat Med 2023;29(11):2909-2918 «PMID: 37840095»PubMed
  19. Garvey WT, Ryan DH, Look M, et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr 2012;95(2):297-308 «PMID: 22158731»PubMed
  20. Davies MJ, Aronne LJ, Caterson ID, et al. Liraglutide and cardiovascular outcomes in adults with overweight or obesity: A post hoc analysis from SCALE randomized controlled trials. Diabetes Obes Metab 2018;20(3):734-739 «PMID: 28950422»PubMed